Nanobiotix S.A. (NASDAQ:NBTX – Get Free Report) saw a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 40,600 shares, a drop of 19.4% from the August 31st total of 50,400 shares. Based on an average daily trading volume, of 9,600 shares, the days-to-cover ratio is currently 4.2 days.
Nanobiotix Stock Up 7.7 %
NASDAQ:NBTX traded up $0.38 during trading hours on Friday, hitting $5.33. 940 shares of the company’s stock traded hands, compared to its average volume of 19,358. The stock’s fifty day moving average price is $5.15 and its two-hundred day moving average price is $5.69. Nanobiotix has a twelve month low of $4.14 and a twelve month high of $9.34.
Analysts Set New Price Targets
Separately, Guggenheim assumed coverage on shares of Nanobiotix in a report on Wednesday, August 28th. They set a “buy” rating and a $12.00 price target on the stock.
About Nanobiotix
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Featured Articles
- Five stocks we like better than Nanobiotix
- What is an Earnings Surprise?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- 3 Monster Growth Stocks to Buy Now
- MarketBeat Week in Review – 9/23 – 9/27
- Airline Stocks – Top Airline Stocks to Buy Now
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
